A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis
ABSTRACT A major obstacle to using current guideline‐recommended chemotherapy in patients with advanced light‐chain cardiac amyloidosis (LCCA) is their intolerance to standard drug dosages. The study aimed to assess the efficacy and safety of the dose‐tailored BD and DBD regimen proposed by our team...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70219 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839627815946813440 |
|---|---|
| author | Yun Ti Huaitao Yu Ying Wang Mei Ni Tongtao Liu Luqun Wang Cheng Zhang Peili Bu Yun Zhang |
| author_facet | Yun Ti Huaitao Yu Ying Wang Mei Ni Tongtao Liu Luqun Wang Cheng Zhang Peili Bu Yun Zhang |
| author_sort | Yun Ti |
| collection | DOAJ |
| description | ABSTRACT A major obstacle to using current guideline‐recommended chemotherapy in patients with advanced light‐chain cardiac amyloidosis (LCCA) is their intolerance to standard drug dosages. The study aimed to assess the efficacy and safety of the dose‐tailored BD and DBD regimen proposed by our team for patients with LCCA at Mayo Stage III. A total of 119 patients who met the inclusion and exclusion criteria for cardiac amyloidosis were recruited and divided into three groups: group A, group B, and group C who received supportive therapy, dose‐tailored BD regimen, and dose‐tailored DBD regimen, respectively. Survival rate and time, hematologic and cardiac response, and adverse events were evaluated during a median follow‐up of 30.2 months. No significant differences in baseline characteristics were found among the three groups. Group B and C showed increased survival rates and time compared to group A. Group C showed improved hematologic and cardiac responses relative to group B. Additionally, group C showed fewer adverse events related to chemotherapy compared to group B. Both dose‐tailored BD and DBD regimens increased survival rates and time in advanced LCCA patients, with the dose‐tailored DBD regimen demonstrating superior efficacy and safety. Further randomized clinical trials are needed to confirm these preliminary findings. |
| format | Article |
| id | doaj-art-c828c746a16a49d6b5f234e93ed7572d |
| institution | Matheson Library |
| issn | 2688-2663 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj-art-c828c746a16a49d6b5f234e93ed7572d2025-07-16T05:18:45ZengWileyMedComm2688-26632025-07-0167n/an/a10.1002/mco2.70219A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac AmyloidosisYun Ti0Huaitao Yu1Ying Wang2Mei Ni3Tongtao Liu4Luqun Wang5Cheng Zhang6Peili Bu7Yun Zhang8State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaDepartment of Hematology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaState Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology Qilu Hospital of Shandong University Jinan ChinaABSTRACT A major obstacle to using current guideline‐recommended chemotherapy in patients with advanced light‐chain cardiac amyloidosis (LCCA) is their intolerance to standard drug dosages. The study aimed to assess the efficacy and safety of the dose‐tailored BD and DBD regimen proposed by our team for patients with LCCA at Mayo Stage III. A total of 119 patients who met the inclusion and exclusion criteria for cardiac amyloidosis were recruited and divided into three groups: group A, group B, and group C who received supportive therapy, dose‐tailored BD regimen, and dose‐tailored DBD regimen, respectively. Survival rate and time, hematologic and cardiac response, and adverse events were evaluated during a median follow‐up of 30.2 months. No significant differences in baseline characteristics were found among the three groups. Group B and C showed increased survival rates and time compared to group A. Group C showed improved hematologic and cardiac responses relative to group B. Additionally, group C showed fewer adverse events related to chemotherapy compared to group B. Both dose‐tailored BD and DBD regimens increased survival rates and time in advanced LCCA patients, with the dose‐tailored DBD regimen demonstrating superior efficacy and safety. Further randomized clinical trials are needed to confirm these preliminary findings.https://doi.org/10.1002/mco2.70219cardiac amyloidosiscardiac responsedose‐tailored anti‐plasma cell regimenheart failurehematologic response |
| spellingShingle | Yun Ti Huaitao Yu Ying Wang Mei Ni Tongtao Liu Luqun Wang Cheng Zhang Peili Bu Yun Zhang A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis MedComm cardiac amyloidosis cardiac response dose‐tailored anti‐plasma cell regimen heart failure hematologic response |
| title | A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis |
| title_full | A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis |
| title_fullStr | A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis |
| title_full_unstemmed | A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis |
| title_short | A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis |
| title_sort | dose tailored anti plasma cell regimen lowers the mortality of late stage cardiac amyloidosis |
| topic | cardiac amyloidosis cardiac response dose‐tailored anti‐plasma cell regimen heart failure hematologic response |
| url | https://doi.org/10.1002/mco2.70219 |
| work_keys_str_mv | AT yunti adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT huaitaoyu adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT yingwang adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT meini adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT tongtaoliu adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT luqunwang adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT chengzhang adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT peilibu adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT yunzhang adosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT yunti dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT huaitaoyu dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT yingwang dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT meini dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT tongtaoliu dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT luqunwang dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT chengzhang dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT peilibu dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis AT yunzhang dosetailoredantiplasmacellregimenlowersthemortalityoflatestagecardiacamyloidosis |